Factor XI Deficiency

Textbook of Hemophilia: Second Edition

Volumn , Issue , 2010, Pages 355-361

  Seligsohn, Uri ^a   Bolton Maggs, Paula H B ^b  

^a TEL AVIV UNIVERSITY   (Israel)

^b MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Biochemical features and function of factor XI; Bleeding manifestations in patients with severe deficiency; Factor XI (FXI) deficiency, described in 1953 as new types of hemophilia; Factor XI deficiency; FXI effect, promoting coagulation and inhibiting fibrinolysis; Heterozygotes and bleeding manifestations; Highest prevalence of FXI deficiency observed in Ashkenazi Jews; Inheritance and functional defect; Negatively charged surfaces triggering activation of factor XII (FXII); Surgery in patients developing inhibitor to FXI, presenting challenges

Indexed keywords

EID: 80053416103     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444318555.ch53     Document Type: Chapter

References (41)

1. Rosenthal R, Dreskin O, Rosenthal N. New hemophilia-like disease caused by deficiency of a third plasma thromboplastin factor. Proc Soc Exp Biol Med 1953; 82: 171-4.
2. Rapaport SI, Proctor RR, Patch NJ, Yettra M. The role of inheritance of PTA deficiency: evidence for the existence of major PTA deficiency and minor PTA deficiency. Blood 1961; 18: 149-65.
3. Seligsohn U. High gene frequency of factor XI (PTA) deficiency in Ashkenazi Jews. Blood 1978; 516: 1223-8.
4. Gailani D, Broze GJ. Factor XI activation in a revised model of blood coagulation. Science 1991; 253: 909-12.
5. Naito K, Fujikawa K. Activation of human blood coagulation factor XI independent of factor XII. Factor XI is activated by thrombin and factor XIa in the presence of negatively charged surfaces. J Biol Chem 1991; 266: 7353-8.
6. Blat Y, Seiffert D. A renaissance for the contact system in blood coagulation? Thromb Hemost 2008; 99: 457-60.
7. Gailani D, Ho D, Sun MF, et al. Model for a factor IX activation complex on blood platelets: dimeric conformation of factor XIa is essential. Blood 2001; 97: 3117-22.
8. Papagrigoriou E, McEwan PA, Walsh PN, Emsley J. Crystal structure of the efactor XI zymogen reveals a pathway for transactivation. Nature Struct Mol Biol 2006; 13: 557-8.
9. Kato A, Asakai R, Davie EW, Aoki N. Factor XI gene ( F11 ) is located on the distal end of the long arm of human chromosome 4. Cytogenet Cell Genet 1989; 52: 77-8.
10. Baglia FA, Badellino KO, Li CQ, et al. Factor XI binding to the platelet glycoprotein Ib-IX-V complex promotes factor XI activation by thrombin. J Biol Chem 2002; 277: 1662-8.
11. Bouma BN, Marx PF, Mosnier LO, Meijers JC. Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U). Thromb Res 2001; 101: 329-54.
12. Asakai R, Chung DW, Davie EW, Seligsohn U. Factor XI defi-ciency in Ashkenazi Jews in Israel. N Engl J Med 1991; 3253: 153-8.
13. Saito H, Ratnoff OD, Bouma BN, Seligshon U. Failure to detect variant (CRM+) plasma thromboplastin antecedent (factor XI) molecules in hereditary plasma thromboplastin antecedent defi-ciency: a study of 125 patients in several ethnic backgrounds. J Lab Clin Med 1985; 106: 718-22.
14. Zivelin A, Ogawa T, Bulvik S, et al. Severe factor XI deficiency caused by a Gly555 to Glu mutation (factor XI - Glu555): a cross-reactive material positive variant defective in factor XI activation. J Thromb Haemost 2004; 2: 1782-9.
15. Asakai R, Chung DW, Ratnoff OD, Davie EW. Factor XI (plasma thromboplastin antecedent) deficiency in Ashkenazi Jews is a bleeding disorder that can result from three types of point mutations. Proc Natl Acad Sci USA 1989; 86: 7667-71.
16. Hancock JF, Wieland K, Pugh RE, et al. A molecular genetic study of factor XI deficiency. Blood 1991; 77: 1942-8.
17. Meijers JC, Mulvihill ER, Davie EW, Chung DW. Apple four in human blood coagulation factor XI mediates dimer formation. Biochemistry 1992; 31: 4680-4.
18. Pugh RE, McVey JH, Truddenham EG, Hancock JF. Six point mutations that cause factor XI deficiency. Blood 1995; 85: 1509-16.
19. Zivelin A, Bauduer F, Ducout L, et al. Factor XI deficiency in French Basques is caused predominantly by an ancestral Cys38Arg mutation in the factor XI gene. Blood 2002; 99: 2448-54.
20. Peretz H, Mulai A, Usher S, et al. The two common mutations causing factor XI deficiency in Jews stem from distinct founders: one of ancient Middle Eastern origin and another of more recent European origin. Blood 1997; 90: 2654-9.
21. Shpilberg O, Peretz H, Zivelin A, et al. One of the two common mutations causing factor XI deficiency in Ashkenazi Jews (type II) is also prevalent in Iraqi Jews, who represent the ancient gene pool of Jews. Blood 1995; 85: 429-32.
22. Goldstein DB, Reich DE, Bradman N, et al. Age estimates of two common mutations causing factor XI deficiency: recent genetic drift is not necessary for elevated disease incidence among Ashkenazi Jews. Am J Hum Genet 1999; 64: 1071-5.
23. Bolton-Maggs PHB, Peretz H, Butler R, et al. A common ancestral mutation (C128X) occurring in 11 non-Jewish families from the UK with factor XI deficiency. J Thromb Haemost 2004; 2: 918-24.
24. Salomon O, Steinberg DM, Seligsohn U. Variable bleeding manifestations characterize different types of surgery in patients with severe factor XI deficiency enabling parsimonious use of replacement therapy. Haemophilia 2006; 12: 490-3.
25. Bolton-Maggs PH, Patterson DA, Wensley RT, Tuddenham EG. Definition of the bleeding tendency in factor XI-deficient kindreds - a clinical and laboratory study. Thromb Haemost 1995; 73: 194-202.
26. Salomon O, Steinberg DM, Tamarin I, et al. Plasma replacement therapy during labor is not mandatory for women with sever factor XI deficiency. Blood Coagul Fibrinolysis 2005; 16: 37-41.
27. Sidi A, Seligsohn U, Jonas P, Many M. Factor XI deficiency: detection and management during urological surgery. J Urol 1978; 119: 528-30.
28. Peyvandi F, Lak M, Mannucci PM. Factor XI deficiency in Iranians: its clinical manifestations in comparison with those of classic hemophilia. Haematologica 2002; 87: 512-14.
29. Bolton-Maggs PH, Young Wan-Yin B, McCraw AH, et al. Inheritance and bleeding in factor XI deficiency. Br J Haematol 1988; 69: 521-8.
30. Brenner B, Laor A, Lupo H, et al. Bleeding predictors in factor-XI-deficient patients. Blood Coagul Fibrinol 1997; 8: 511-15.
31. Salomon O, Steinberg DM, Dardik R, et al. Inherited factor XI deficiency confers no protection against acute myocardial infarction. J Thromb Haemost 2003; 1: 658-61.
32. Salomon O, Steinberg DM, Koren-Morag N, et al. Reduced incidence of ischemic stroke in patients with severe factor XI defi-ciency. Blood 2008; 111: 4113-17.
33. Brodsky JB, Burgess GE. Pulmonary embolism with factor XI deficiency. JAMA 1975; 234: 1156-7.
34. Meijers JC, Tekelenburg WL, Bouma BN, et al. High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med 2000; 342: 696-701.
35. Gailani D, Broze GJ. Factor XI and the contact system. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds.) The Metabolic and Molecular Basis of Inherited Diseases, 8th edn. New York: McGraw-Hill Publishing, 2000: 4433-4453.
36. Seligsohn U, Zitman D, Many A, Klibansky C. Coexistence of factor XI (plasma thromboplastin antecedent) deficiency and Gaucher ' s disease. Isr J Med Sci 1976; 12: 1448-52.
37. Salomon O, Ziveiln A, Livnat T, et al. Prevalence, causes, and characterization of factor XI inhibitors in patients with inherited factor XI deficiency. Blood 2003; 101: 4783-88.
38. Seligsohn U, Modan M. Definition of the population at risk of bleeding due to factor XI deficiency in Ashkenazic Jews and the value of activated partial thromboplastin time in its detection. Isr J Med Sci 1981; 17: 413-15.
39. Bolton-Maggs PHB. Factor XI deficiency and its management. Haemophilia 2000; 6: 100-9.
40. Berliner S, Horowitz I, Martinowitz U, et al. Dental surgery in patients with severe factor XI deficiency without plasma replacement. Blood Coagul Fibrinol 1992; 3: 465-8.
41. Livnat T, Tamarin I, Mor Y, et al. Recombinant activated factor VII and tranexamic acid are hemostatically effective during major surgery in factor XI-deficient patients with inhibitor antibodies. Thromb Haemost 2009; 102: 487-92.